Cathie Wood’s Stock Portfolio: 2025 Stock Picks

Page 6 of 14

9. CRISPR Therapeutics AG (NASDAQ:CRSP)

ARK Investment Management’s Q3 Stake Value: $352.2 million

Number of Hedge Fund Holders: 27

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to produce precise cures for diseases that need DNA tampering. CASGEVY, the company’s flagship medication developed in collaboration with Vertex Pharmaceuticals, was one of the first gene-edited treatments on the market.

CRISPR Therapeutics AG (NASDAQ:CRSP) reported a solid balance sheet for the third quarter of 2024, with around $1.9 billion in marketable securities, cash, and cash equivalents. With a rich pipeline, a solid balance sheet, and an approved commercial product, the company is poised to grow its pipeline in 2025.

CRISPR Therapeutics AG (NASDAQ:CRSP) recently announced its 2025 strategic goals, with a focus on updates on several key development initiatives and the ongoing rollout of its gene-based medication CASGEVY. The FDA has designated the company’s CTX112 as a regenerative medicine advanced therapy (RMAT), and CTX131 is currently undergoing clinical trials. Furthermore, clinical trials for the company’s in vivo cardiovascular programs, including CTX310 and CTX320, are currently underway.

Page 6 of 14